| Seely, Andrew |
POISE, NCT04871412: The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III |
|
|
| Recruiting | 3 | 20 | Canada | Vitamin D3 Drops, Vitamin D, Coriolus Versicolor, Trident SAP 66:33 Lemon, Fish Oil, Probiotic Pro12, Probiotics, Provitalix Pure Whey Protein, Protein Powder, Theracurmin 2X, Curcumin, Green Tea Extract, EGCG, Nutrition Recommendations, Physical Activity Recommendations, Psychological Recommendations | Ottawa Hospital Research Institute, The Canadian College of Naturopathic Medicine, Lotte & John Hecht Memorial Foundation, The Centre for Health Innovation, University of Ottawa | Lung Cancer, Gastric Cancer, Esophageal Cancer | 12/29 | 12/31 | | |
NCT04708509: Extubation Advisor: Initial Implementation and Evaluation of a Novel Extubation Clinical Decision Support Tool |
|
|
| Recruiting | 1 | 72 | Canada | Extubation Advisor | Ottawa Hospital Research Institute | Airway Extubation | 01/23 | 02/23 | | |
| Not yet recruiting | N/A | 72 | Canada, US | Venovenous ECMO | University of Toronto, University Health Network, Toronto | ARDS | 06/23 | 12/23 | | |
NCT04661787: Donation Advisor Clinical Decision Support Tool Study |
|
|
| Recruiting | N/A | 70 | Canada | | Ottawa Hospital Research Institute, Gift of Life, Canadian Blood Services, Health Canada, Canadian National Transplant Research Program, The Physicians' Services Incorporated Foundation, The Ottawa Hospital, Unity Health Toronto, Queen's University, London Health Sciences Centre, Sunnybrook Health Sciences Centre, Hamilton Health Sciences Corporation, University Health Network, Toronto | Organ Donation | 11/23 | 12/23 | | |
LEADS, NCT05506904: Liberation From Mechanical Ventilation Using Extubation Advisor Decision Support |
|
|
| Recruiting | N/A | 100 | Canada | Extubation Advisor | Ottawa Hospital Research Institute | Airway Extubation | 03/25 | 06/25 | | |
VSI, NCT05108376: Feasibility and Initial Clinical Impressions of Predictive Monitoring Integrated With the RACE Team |
|
|
| Not yet recruiting | N/A | 140 | Canada | Visensia Safety Index (VSI) | Ottawa Hospital Research Institute | Deterioration, Clinical | 01/24 | 01/24 | | |
HONOUR, NCT05078034: HNFO With or Without Helmet NIV for Oxygenation Support in Acute Respiratory Failure Pilot RCT |
|
|
| Recruiting | N/A | 200 | Canada | Helmet Non-Invasive Ventilation (HNIV), HNIV, High Flow Nasal Oxygen, HFNO | Sunnybrook Health Sciences Centre | Acute Hypoxemic Respiratory Failure | 02/25 | 02/25 | | |
| Recruiting | N/A | 80 | Canada | Amiodarone, Placebo | Ottawa Hospital Research Institute | Atrial Fibrillation | 03/24 | 04/24 | | |
REVIVe, NCT05246098: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI |
|
|
| Recruiting | N/A | 900 | Canada | | McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group | Respiratory Disease, COVID-19, Viral Infection | 03/25 | 10/25 | | |
| Recruiting | N/A | 200 | Canada | | Ottawa Hospital Research Institute | Achalasia, Paraesophageal Hernia, GERD, Epiphrenic Diverticula, Zenker's Diverticulum | 11/27 | 11/27 | | |
| Weberpals, Johanne I |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer |
|
|
| Active, not recruiting | 2 | 125 | Europe, Canada, US, RoW | Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel | Tesaro, Inc. | Ovarian Neoplasms | 08/25 | 04/27 | | |
|
| Recruiting | N/A | 510 | Canada | Tumour tissue collection, Blood sample collection, Ascites Collection, Fluid Collection | University Health Network, Toronto | Gynecologic Cancer | 06/26 | 06/26 | | |
| Le, Mai H |
(CMRG)-008, NCT04786028: A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM |
|
|
| Active, not recruiting | 2 | 72 | Canada | Isatuximab | Canadian Myeloma Research Group | Multiple Myeloma | 03/26 | 06/27 | | |
| Recruiting | N/A | 48 | US | Manual Standing Wheelchair, Levo Summit Wheelchair, Mobile Manual Standing Wheelchair, Modified Levo Summit Wheelchair | VA Office of Research and Development | Spinal Cord Injuries and Disorders | 06/25 | 08/25 | | |
| Sarti, Aimee |
NCT04708509: Extubation Advisor: Initial Implementation and Evaluation of a Novel Extubation Clinical Decision Support Tool |
|
|
| Recruiting | 1 | 72 | Canada | Extubation Advisor | Ottawa Hospital Research Institute | Airway Extubation | 01/23 | 02/23 | | |
| Cameron, Bill |
NCT04258475: The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. |
|
|
| Recruiting | 4 | 12 | Canada | Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily., RAL, Isentress®, Calcium carbonate antacid tablet, TUMS® Ultra Strength (US) 500 mg | Ottawa Hospital Research Institute | Calcium Supplementation in HIV Patients Using Raltegravir | 06/24 | 01/25 | | |
| Recruiting | 2 | 10 | Canada | Vedolizumab (brand name Entyvio) | Ottawa Hospital Research Institute, CHEO Research Institute, Nebraska Centre for Substance Abuse Research | HIV-infection/AIDS | 12/23 | 12/23 | | |
| Maziak, Donna E |
NCT03310125 / 2017-003836-35: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) |
|
|
| Completed | 3 | 3209 | Europe, Canada, US, RoW | Colchicine, Placebo | Population Health Research Institute, Hamilton Health Sciences Corporation | Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery | 07/23 | 07/23 | | |
| Recruiting | N/A | 80 | Canada | Amiodarone, Placebo | Ottawa Hospital Research Institute | Atrial Fibrillation | 03/24 | 04/24 | | |
| Recruiting | N/A | 200 | Canada | | Ottawa Hospital Research Institute | Achalasia, Paraesophageal Hernia, GERD, Epiphrenic Diverticula, Zenker's Diverticulum | 11/27 | 11/27 | | |
| Carrier, Marc |
SAFE-SSPE, NCT04263038: Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism |
|
|
| Recruiting | 4 | 276 | Europe, Canada | Rivaroxaban, Placebo | Drahomir Aujesky, University of Bern, Schweizerischer Nationalfonds, Leiden University Medical Center, The Ottawa Hospital, Bayer | Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases, Cardiovascular Diseases, Respiratory Tract Diseases, Venous Thromboembolism, Anticoagulant-induced Bleeding, Bleeding | 05/26 | 05/26 | | |
NCT05255003: STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis |
|
|
| Recruiting | 4 | 50 | Canada | Enoxaparin, Lovenox, Dalteparin, Fragmin, Tinzaparin, Innohep | Ottawa Hospital Research Institute | Cancer-associated Thrombosis, Thrombocytopenia | 10/24 | 03/25 | | |
CONQUER-DVT, NCT06440694: Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) |
|
|
| Not yet recruiting | 3 | 150 | Canada | Colchicine 0.5 mg po, Myinfla tablet 0.5 mg po daily, Placebo 0.5 mg po, Placebo 0.5 mg po daily | Ottawa Hospital Research Institute | Venous Thromboembolism | 12/27 | 12/27 | | |
| Completed | 3 | 1767 | Europe, Canada | Apixaban 5 MG, Apixaban 2.5 MG | Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb | Cancer-associated Thrombosis | 09/24 | 10/24 | | |
| Recruiting | 3 | 1828 | Canada | Rivaroxaban 10 MG, Placebo | Ottawa Hospital Research Institute | Venous Thromboembolism, Cancer | 12/26 | 12/27 | | |
| Recruiting | 3 | 4000 | Canada, US, RoW | Heparin | University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI | Community-acquired Pneumonia | 03/28 | 03/29 | | |
PrOVE iT, NCT06662253: Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial |
|
|
| Not yet recruiting | 2/3 | 150 | NA | Anti-Xa Guided Dosing of Low Molecular Weight Heparin, Standard of Care Dosing | Alexandre Tran | Venous Thromboembolism (VTE), Trauma Related Injuries | 06/26 | 09/26 | | |
| Recruiting | 2/3 | 120 | Canada | Rivaroxaban 10 MG, Xarelto, Placebo control | Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Kidney Cancer Research Network of Canada | Venous Thromboembolism, Urologic Cancer | 10/26 | 10/26 | | |
WAVe, NCT03297359: Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism |
|
|
| Terminated | 2 | 92 | Canada | Dalteparin | Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network | Cancer, Venous Thromboembolism, Obesity | 11/23 | 11/23 | | |
| Recruiting | N/A | 1276 | Europe, Canada | Limited cancer screening, Limited cancer screening + FDG PET/CT | University Hospital, Brest, Ministry of Health, France, Canadian Institutes of Health Research (CIHR), Ottawa Hospital Research Institute | Embolism and Thrombosis | 09/26 | 09/30 | | |
| Kapur, Atul |
INITIATE, NCT04163081: The Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments |
|
|
| Recruiting | N/A | 1208 | Canada | Quit Card Intervention (QCI) | Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR) | Nicotine Dependence, Cigarettes, Nicotine Withdrawal | 08/25 | 03/27 | | |
| Christink, Kendra |
| Recruiting | 2 | 70 | Canada | Neoadjuvant | Ontario Clinical Oncology Group (OCOG), Hoffmann-La Roche | Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis | 06/26 | 06/26 | | |
| Recruiting | N/A | 10000 | Canada | | University Health Network, Toronto, Princess Margaret Hospital, Canada | Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer | 08/26 | 08/26 | | |
| Villeneuve, James |
| Recruiting | 4 | 2270 | Europe, Canada, RoW | Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban | Population Health Research Institute, Hamilton Health Sciences Corporation | Stroke, Atrial Fibrillation | 12/26 | 12/28 | | |
| Villeneuve, Pierre |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
|
EASE, NCT04224974: Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia |
|
|
| Recruiting | N/A | 266 | Canada | Usual Care, EASE-psy | Canadian Cancer Trials Group, Canadian Cancer Society (CCS), Canadian Institutes of Health Research (CIHR), Princess Margaret Hospital, University Health Network | Acute Leukemia | 12/24 | 12/24 | | |
| MacFadden, Derek |
| Recruiting | 4 | 8000 | Europe, Canada, RoW | Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging | University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute | Staphylococcus Aureus Bacteremia | 12/28 | 12/28 | | |
TAPER-V, NCT04138706: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection |
|
|
| Active, not recruiting | 3 | 263 | Canada | Vancomycin, Placebos | McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR) | Clostridium Difficile Infection | 10/24 | 10/24 | | |
| Recruiting | N/A | 1440 | Canada | Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis, Decision Support Tool | Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR) | Sepsis, Bacterial Infections, Community-Acquired Infections, Hospital Infection | 03/25 | 06/25 | | |
| Recruiting | N/A | 550 | Canada, US | Start Antibiotics / Continue Antibiotics for treatment of bacteriuria, No Antibiotics for treatment of bacteriuria | Mount Sinai Hospital, Canada, Sault Area Hospital, Michael Garron Hospital, Unity Health Toronto, The Ottawa Hospital, Northwestern Memorial Hospital | Infectious Disease | 09/27 | 09/27 | | |
| Tremblay, Nancy |
NCT04258475: The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. |
|
|
| Recruiting | 4 | 12 | Canada | Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily., RAL, Isentress®, Calcium carbonate antacid tablet, TUMS® Ultra Strength (US) 500 mg | Ottawa Hospital Research Institute | Calcium Supplementation in HIV Patients Using Raltegravir | 06/24 | 01/25 | | |
